CNTO 6785

Drug Profile

CNTO 6785

Alternative Names: CNTO-6785

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Janssen; MorphoSys
  • Developer Janssen
  • Class Antirheumatics
  • Mechanism of Action Immunostimulants; Interleukin 17 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic obstructive pulmonary disease; Rheumatoid arthritis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Rheumatoid-arthritis(In volunteers) in Belgium (IV, Infusion)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Rheumatoid-arthritis(In volunteers) in Belgium (SC, Injection)
  • 01 Jun 2015 Janssen Research & Development completes a phase II trial in Rheumatoid arthritis in Argentina, Colombia, Czech Republic, Poland, Russia, Thailand and Philippines (NCT01909427)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top